Dr Luc Otten joined Vinci Capital in October 2010 from Helvea where he was working as equity research analyst in the biotech and pharma industry since 2008. In Helvea, a leading Swiss brokerage company and spin-off of Pictet & Cie, he conducted company research (Ablynx, Actelion, Arpida, BioInvent, Galenica, Genmab and MorphoSys). He also produced sector reports on GLP1 drugs for treating diabetes and monoclonal antibodies.
Dr Otten studied Medicine in Geneva with internships in Australia, and holds a doctorate in Medicine and Biology from the University of Geneva. He also holds a Certificate of Advanced Studies in Management of Biotech, Medtech and Pharma Ventures from EPFL (Lausanne).
Vinci Capital - PSE-C - CH-1015 Lausanne - Tel +41 (0)21 693 92 34 - info@vincicapital.ch
Vinci Capital
PSE Bâtiment C
CH-1015 Lausanne
Tel +41 (0)21 693 92 34
